Spectral Diagnostics Inc.
Spectral’s vision is to provide products that will enable vastly improved outcomes of patients with severe sepsis.
This company is nowadays conducting a Phase III clinical trial for its lead product, Toraymyxin, for the treatment of patients with septic shock. Spectral aims to win the battle against sepsis mortality with the first ever theranostic EAA™ and Toraymyxin.
Generally, Spectral’s vision is to provide products that will enable vastly improved outcomes of patients with severe sepsis.
Generally, Spectral’s vision is to provide products that will enable vastly improved outcomes of patients with severe sepsis.
Business Type: Nanotextile » | Biotechnology » | Electrotechnics » |
Spectral Diagnostics Inc.135 The West Mall , Unit 2 |
Share with friends:
Nanotechnology in medicine | Nano materials | Nanotechnology electronics | Nano asociation |
Follow Nanotechnology Journal on
© 2008 - 2020 Nanotechnology research | All rights reserved | Developed by Makovic.net